{
    "organizations": [],
    "uuid": "d180d5414fd2e5093de06e80eb1b8878b27567e1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-allergan-exercises-option-to-acqui/brief-allergan-exercises-option-to-acquire-compound-from-aptinyx-discovery-platform-idUSFWN1ST0DH",
    "ord_in_thread": 0,
    "title": "BRIEF-Allergan Exercises Option To Acquire Compound From Aptinyx Discovery Platform",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 22 (Reuters) - Allergan plc:\n* ALLERGAN EXERCISES OPTION TO ACQUIRE COMPOUND FROM APTINYX DISCOVERY PLATFORM UNDER ONGOING RESEARCH COLLABORATION\n* APTINYX - ALLERGAN EXERCISED OPTION TO ACQUIRE DRUG CANDIDATE AGN-241751, AN ORAL SMALL-MOLECULE N-METHYL-D-ASPARTATE Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-05-22T20:49:00.000+03:00",
    "crawled": "2018-05-23T14:59:59.022+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "allergan",
        "plc",
        "allergan",
        "exercise",
        "option",
        "acquire",
        "compound",
        "aptinyx",
        "discovery",
        "platform",
        "ongoing",
        "research",
        "collaboration",
        "aptinyx",
        "allergan",
        "exercised",
        "option",
        "acquire",
        "drug",
        "candidate",
        "oral",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}